leadf
logo-loader
viewC4X Discovery Holdings PLC

C4X Discovery CEO welcomes start of Indivior trial and outlines new coronavirus venture

C4X Discovery PLC's (LON:C4XD) Chief Executive Clive Dix speaks to Proactive London about the start of clinical trials of a treatment for opioid dependence.

The phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year. Dix also discusses the company's new partnership with the GEN-COVID Consortium in Italy.

 

 

Quick facts: C4X Discovery Holdings PLC

Price: 17.5 GBX

AIM:C4XD
Market: AIM
Market Cap: £20.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: FTSE 100 on the up as airline stocks surge higher

Headlines from the Proactive UK newsroom. The FTSE 100 index rose again as airline stocks surged higher. British Airways owner IAG led the way climbing 11% in the morning while the index jumped 71 to 6,412. AstraZenecasays it will soon be able to supply two billion doses of a potential...

on 5/6/20

2 min read